NADAC acquisition cost data for COSENTYX (150 MG/ML) 300 MG DOSE-2 PENS. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00078063941 | $3,133.71 | 2022-07-27 | Rx |
| 00078063941 | $3,133.71 | 2022-07-27 | Rx |
| 00078063941 | $3,133.71 | 2022-07-27 | Rx |
| 00078063941 | $3,133.71 | 2022-07-27 | Rx |
| 00078063941 | $3,133.71 | 2022-07-27 | Rx |
| 00078063941 | $3,133.71 | 2022-07-27 | Rx |
| 00078063941 | $3,133.71 | 2022-07-27 | Rx |
| 00078063941 | $3,133.71 | 2022-07-27 | Rx |
| 00078063941 | $3,133.71 | 2022-07-27 | Rx |
| 00078063941 | $3,133.71 | 2022-07-27 | Rx |
Generic: Secukinumab | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $48.3M | 7,082 | 1,413 | $2,628.73 |
| 2020 | $58.5M | 8,274 | 1,528 | $2,807.89 |
| 2021 | $66.5M | 9,225 | 1,601 | $3,001.10 |
| 2022 | $76.6M | 10,118 | 1,707 | $3,227.11 |
| 2023 | $83.1M | 10,428 | 1,677 | $3,539.01 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $9.4M | 1,379 | 237 |
| Texas | $5.9M | 732 | 126 |
| Florida | $5.8M | 693 | 121 |
| New York | $5.3M | 581 | 112 |
| Michigan | $3.8M | 469 | 79 |
| Ohio | $3.3M | 434 | 69 |
| Washington | $2.9M | 405 | 59 |
| Massachusetts | $2.9M | 338 | 49 |
| North Carolina | $2.9M | 339 | 58 |
| Indiana | $2.7M | 314 | 53 |
| Pennsylvania | $2.5M | 306 | 55 |
| Illinois | $2.4M | 284 | 44 |
| Georgia | $2.4M | 285 | 48 |
| New Jersey | $2.2M | 266 | 43 |
| South Carolina | $2.1M | 262 | 34 |
| Kentucky | $1.7M | 229 | 32 |
| Tennessee | $1.7M | 212 | 38 |
| Colorado | $1.7M | 239 | 37 |
| Arizona | $1.5M | 178 | 36 |
| Wisconsin | $1.5M | 197 | 31 |
| Oregon | $1.5M | 192 | 32 |
| Louisiana | $1.4M | 166 | 23 |
| Missouri | $1.3M | 168 | 32 |
| Oklahoma | $1.3M | 165 | 24 |
| Minnesota | $1.2M | 150 | 25 |
| Maryland | $1.2M | 153 | 30 |
| Alabama | $1.2M | 137 | 18 |
| Virginia | $1.1M | 139 | 21 |
| Arkansas | $757.5K | 94 | 12 |
| Idaho | $721.9K | 87 | 12 |
| Connecticut | $701.4K | 90 | 15 |
| New Hampshire | $595.5K | 71 | N/A |
| Nebraska | $570.6K | 69 | N/A |
| West Virginia | $500.2K | 61 | N/A |
| Kansas | $492.0K | 54 | N/A |
| Maine | $482.7K | 46 | 13 |
| Puerto Rico | $464.5K | 62 | N/A |
| Nevada | $451.7K | 54 | N/A |
| Iowa | $401.2K | 46 | N/A |
| Mississippi | $390.5K | 46 | 11 |
| Rhode Island | $272.2K | 27 | N/A |
| Montana | $236.8K | 33 | N/A |
| Utah | $186.2K | 22 | N/A |
| Wyoming | $164.3K | 22 | N/A |
| Hawaii | $158.9K | 16 | N/A |
| District of Columbia | $152.1K | 31 | N/A |
| Delaware | $148.5K | 21 | N/A |
| New Mexico | $133.3K | 16 | N/A |
| South Dakota | $132.7K | 12 | N/A |
| North Dakota | $132.5K | 17 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.